---
title: 'Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid
  Leukemia: Results of a Phase 1b Study'
date: '2025-02-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39919267/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250208170414&v=2.18.0.post9+e462414
source: Blood
description: Venetoclax combined with intensive chemotherapy shows promise for untreated
  acute myeloid leukemia (AML), but its integration with the '7+3' regimen remains
  underexplored. In a phase 1b study (NCT05342584), we assessed the safety and efficacy
  of venetoclax with daunorubicin and cytarabine in newly diagnosed AML patients.
  Thirty-four patients (median age 59 years; 62% non-white) received venetoclax at
  escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia
  ...
disable_comments: true
---
Venetoclax combined with intensive chemotherapy shows promise for untreated acute myeloid leukemia (AML), but its integration with the '7+3' regimen remains underexplored. In a phase 1b study (NCT05342584), we assessed the safety and efficacy of venetoclax with daunorubicin and cytarabine in newly diagnosed AML patients. Thirty-four patients (median age 59 years; 62% non-white) received venetoclax at escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia ...